A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, with respect to efficacy, cycle control, and tolerance

Contraception

Volumn 55, Issue 3, 1997, Pages 131-137

  Endrikat, Jan ^a   Muller U ^a   Dusterberg B ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

cycle control; ethinylestradiol; gestodene

Indexed keywords

ETHINYLESTRADIOL PLUS GESTODENE; LOW DOSE ORAL CONTRACEPTIVE; SH D 356C; SH D 543A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL;

CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, FEMALE--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE AGENTS--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE EFFECTIVENESS; CONTRACEPTIVE METHODS; CONTRACEPTIVE USAGE; DEVELOPED COUNTRIES; DISEASES; ETHINYL ESTRADIOL--ADMINISTRACTION AND DOSAGE; EUROPE; FAMILY PLANNING; GERMANY; GESTODENE; MENSTRUATION DISORDERS; METHOD ACCEPTABILITY; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, LOW-DOSE; RESEARCH METHODOLOGY; WESTERN EUROPE;

ADULT; AMENORRHEA; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DOUBLE-BLIND METHOD; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; GERMANY; HUMANS; INCIDENCE; MENSTRUATION; NORPREGNENES; TIME FACTORS; UTERINE HEMORRHAGE;

EID: 0343765846     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00025-5     Document Type: Article

References (9)

1. Gerstman B, Piper J, Timita D, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
2. Fitzgerald C, Feichtinger W, Spona J, et al. A comparison of the effects of two monophasic low-dose oral contraceptives on the inhibition of ovulation. Adv Contracept 1994;10:5-18.
3. Elomaa K, Moorrees M, De Prest J, et al. Extension of the pill-free period by three days in oral contraceptive users. FIGO Montreal 1994; Abstract 04.27.
4. Düsterberg B, Ellman H, Müller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996;10: 33-9.
5. Fotherby K, Caldwell A. New progestogens in oral contraception. Contraception 1994;49:l-33.
6. Brill K, Schnitker J, Albring M. Clinical experience with a modern low-dose gestodene-containing oral contraceptive in adolescents. Adv Contracept 1994;10:237-47.
7. Akerlund M, Rode A, Westergaard J, et al. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150μg desogestrel and either 30μg or 20μg ethinylestradiol. Br J Obstet Gynaecol 1993;100:832-8.
8. Latin American Oral Contraceptive Study Group. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinylestradiol and desogestrel/ethinylestradiol. Contraception 1994;50:201-14.
9. Endrikat J, Jaques M, Mayerhofer S, et al. A twelvemonth comparative clinical investigation of two lowdose oral contraceptives containing 20μg ethinylestradiol/75μg gestodene and 20μg ethinylestradiol/150μg desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995;52:229-35.